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 A multi-functional nanostructured lipid carrier (M-NLC) can penetrate the blood brain 
barrier (BBB) after proper surface functionalization and deliver its therapeutic cargo 
in the diseased tissue. 
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Abstract 
Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) comprise a 
category of versatile drug delivery systems that have been used in the biomedical field 
for more than 25 years. SLNs and NLCs have been used for the treatment of various 
diseases including cardiovascular and cerebrovascular, and are considered a standard 
treatment for the latter, due to their inherent ability to cross the blood brain barrier 
(BBB). In this review, a presentation of the most important brain diseases (brain 
nd multiple 
sclerosis) is approached, followed by the basic fabrication techniques of SLNs and 
NLCs. A detailed description of the reported studies of the last seven years, of active 
and passive targeting SLNs and NLCs for the treatment of glioblastoma multiforme 
and of other brain cancers, as well as for the treatment of neurodegenerative diseases 
is also carried out. Finally, a brief description of the advantages, the disadvantages, 
and the future perspectives in the use of these nanocarriers is reported, aiming at 
giving an insight of the limitations that have to be overcome in order to result in a 
delivery system with high therapeutic efficacy and without the limitations of the 
existing nano-systems. 
 
Keywords: SLNs, NLCs, Neurodegenerative diseases, Glioblastoma multiforme, 
BBB. 
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1. Introduction 
Over the years, numerous nanostructures of various sizes and shapes have been 
reported in the literature for the treatment of different diseases. These nanostructures 
are comprised by various materials either synthetic or natural, and their properties 
vary depending on the materials used and the functionalization they undergo. It has 
been more than 50 years since the first appearance of spherical nano/microstructures 
[1], and during these years these structures have been evolved and found use in many 
industrial and biomedical applications. In the biomedical field, the evolution of 
various nanostructures, organic and inorganic, has been rapid due to the imminent 
need to replace conventional strategies of treating untreatable diseases. In fact, the 
unmet clinical needs of many diseases were the leading cause for the development of 
nanostructures with tailored properties, aiming at fabricating a superior drug delivery 
system, which will specifically target diseased tissues without affecting its healthy 
niece. Nano-medicinal carriers have been used for the treatment of various diseases 
including cancer [2,3], atherosclerosis [4 6], intervertebral disc degeneration [7,8], 
cardiovascular diseases [9,10], and cerebrovascular diseases [11,12]. 
Due to the complexity of each pathology, each nanostructure has to be properly 
studied and designed in order to achieve the maximum therapeutic effect with the 
lowest possible side effects. Most of these nanostructures can be modified in a way 
that makes them responsive to various internal or external stimuli, a property which is 
useful for the controlled release of encapsulated therapeutic substances. A significant 
number of these nanostructures, such as inorganic nanoparticles or other 
polymeric/lipid nanoparticles, have also been used as diagnostic tools. The 
combination of therapy and diagnosis led to the fabrication of theranostic  
nanoparticles, but unfortunately, to date, most of these theranostic devices make use 
only of synthetic polymers and not of lipid-based nanostructures such as solid lipid 
nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). 
Among the diseases that these nanostructures target, we find conditions that affect the 
central nervous system (CNS), the most important of which are brain cancer, ischemic 
stroke (IS)  (PD)  (AD) and multiple 
sclerosis (MS). The cause of appearance is different for each disease, and it is affected 
by genetic and/or environmental factors. This diversity is one of the reasons that the 
design of drug delivery systems has to be very specific in order to successfully target 
the diseased area without affecting the surrounding tissues, and to result in its 
regression or even its complete cure. Even though all the CNS diseases have a 
different cause, they all share a common characteristic in terms of targeted delivery, 
and this characteristic is the blood-brain barrier (BBB). BBB is one of the main 
reasons why the delivery of therapeutic molecules inside the brain is so complex. The 
tight junctions of the endothelial cells make almost impossible each attempt of 
delivering drugs into the brain if they are not functionalized with specific targeting 
segments or if they are not encapsulated inside other nanostructures. In order to 
overcome this limitation, current therapeutics like drugs, antioxidants, enzymes, 
genes, DNA/RNA and/or inorganic nanoparticles are properly cloaked inside 
polymeric or lipid nanostructures that have the ability to penetrate the BBB (Figure 
1). In the literature, most of the nanoparticulate delivery systems that have been used 
for treating brain diseases are comprised by synthetic polymers like polyethylene 
glycol (PEG) or poly (lactide-co-glycolide) (PLGA) [11 14]. These polymeric 
nanostructures present versatility in their size, shape, physicochemical properties, and 
surface functionalization, that allows them to penetrate the BBB and to deliver their 
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encapsulated cargo in a controlled and sustained way. Nevertheless, most of these 
nanoparticulate systems present toxicity issues due to the acidic by-products that are 
formed during their degradation, rendering them inappropriate for extended use in the 
brain. An alternative approach with respect to these polymeric nanoparticles is 
represented by either inorganic nanoparticles (that indeed also present an inherent 
toxicity) and lipid-based structures. Liposomes, solid lipid nanoparticles, and 
nanostructured lipid carriers are the most important representatives of the lipid-based 
nanosystems, and they have been used for the treatment of brain diseases in the last 30 
years. These lipid nanostructures are more biocompatible if compared to the 
polymeric or inorganic nanoparticles, and they have an inherent ability, due to their 
small size and to their lipid nature, to penetrate the BBB even without any 
functionalization. One more advantage of these nanostructures compared to the 
synthetic polymers is the possibility of their production at large scale, and this is one 
of the reasons why these nanostructures are becoming more and more attractive as a 
DDS. Unfortunately, to date, very few of these systems have been in clinical trials or 
commercially available, and one of the possible reasons is their major drawback 
which lies to their low loading capacity. 
The reported literature on polymeric and lipid-based nanoparticulate systems for the 
treatment of CNS diseases is extensive, and in this review, we are going to briefly 
describe the advances in the synthesis, characterization, and in vitro/in vivo studies for 
SLNs and NLCs that were carried out during the last seven years. Briefly herein, we 
are describing the most important brain diseases and some of their main 
characteristics, followed by a description of the type of lipid-based nanostructures and 
their fabrication techniques. Finally, an extensive report to the literature on active and 
passive targeted SLNs and NLCs for CNS, followed by the conclusions and the future 
perspectives for this type of delivery systems, is carried out. 
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2. Solid lipid nanoparticles and nanostructured lipid carriers: synthesis, 
characterization, and comparison with other DDSs 
2.1. Type of lipid carriers 
Lipid-based carriers can be divided into various categories depending on their 
physicochemical properties and the method that is used for their fabrication. The main 
lipid-based carriers include 1) niosomes, which are lamellar self-assembled structures 
that comprise of non-ionic surfactants and cholesterol [15,16], 2) transferosomes, 
which are similar to niosomes and to liposomes and they consist of a lipid bilayer 
created by a lipid matrix that is stabilized by a variety of surfactants [17], 3) 
liposomes, which are spherical vesicles created by a lipid bilayer of phospholipids 
[18,19], 4) solid lipid nanoparticles which consist of a solid lipid core at room and 
body temperature [20], and 5) the nanostructured lipid carriers, the core of which 
comprises a liquid lipid phase inside the solid lipid phase [21]. 
Although all of the above-mentioned nanostructures have been used as drug delivery 
systems for treating brain diseases [20 26], this review will focus only on two types 
of lipid-based nanocarriers, the SLNs and the NLCs. 
 
2.1.1. Solid lipid nanoparticles 
Solid lipid nanoparticles are one of the newest members of the lipid-based 
nanocarriers family and they made their first appearance almost twenty-five years ago 
[27 29]. The need of overcoming the limitations of other nanostructured systems 
(niosomes, transfersomes, micelles, liposomes, emulsions, polymeric nanoparticles) 
like toxicity, stability and low loading capacities led to their fast development, and 
since then many studies demonstrating their usefulness in numerous diseases have 
been published [20,30,31]. 
SLNs are fabricated using a variety of lipids that share common characteristics 
including low melting point and solidness at ambient and body temperature, and a 
variety of surfactants and/or co-surfactants. Some of the main lipids that have been 
used to date are, monostearin, stearyl alcohol, stearic acid, glycerol monostearate, 
Precirol® ATO5, Compritol® 888 ATO, cetyl palmitate, while some of the main 
surfactants that act also as stabilizers are, poloxamer 188, Tween® 80 and dimethyl 
dioctadecyl ammonium bromide (DDAB). The proper selection of lipids and 
surfactants as well as the composition of SLNs, approximately 0.1  30% w/w for the 
solid core and 0.5  5% w/v for the surfactants, affects their physicochemical 
properties such as size, polydispersity, surface charge, short and long-term stability, 
drug loading and release profile. 
One of the main reasons for the fast development of SLNs was their ability to 
effectively deliver in numerous diseased tissues both lipophilic and hydrophilic drugs, 
as well as other therapeutic molecules including oligonucleotides, peptides, genes and 
even smaller nanoparticles such as superparamagnetic iron oxide nanoparticles. One 
more advantage of the SLNs is that they reduce the toxicity of the therapeutic 
molecule that they transfer protecting them, at the same time, from reticuloendothelial 
system (RES) clearance. Their inherent ability of poor solubility in water acts also in 
favor of the encapsulated substance since it results into controlled and sustained 
release profiles; moreover, their long-term stability allows them to be used for long 
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periods of time. SLNs are also biocompatible, can be easily sterilized and the used 
fabrication methods do not require the use of organic solvents which may affect the 
toxicity of the final product. Moreover, the fabrication of these lipid nanocarriers can 
be easily scaled up allowing them to be used at industrial scale. Finally, 
functionalization of the SLNs with specifically modified targeting lipids allows them 
to actively target desired tissues. Although SLNs have many benefits, they also have a 
few disadvantages, some of which are the expulsion of the encapsulated therapeutic, 
the tendency to gelate, and the low encapsulation efficiency (EE) [30][20]. It has to be 
noted, that the low encapsulation efficiency results from the internal structure of the 
lipid core, which during crystallization does not allow the creation of empty spaces, 
making difficult for a potential encapsulated substance to remain trapped inside the 
solid phase. 
 
2.1.2. Nanostructured lipid carriers 
Aiming at improving the inherent disability of SLNs for high loading efficiency, 
Müller et al. [32] proposed a modified version of SLNs where the structure of the 
solid lipid core contains imperfections that increase the internal free space of the 
solid, resulting in higher payloads. To achieve this imperfect crystal structure, mixing 
of liquid lipids with the solid lipid as well as the use of lipids like mono-, di- and 
triglycerides with different chain lengths, can lead to the desired result [30]. This next 
generation of SLNs not only presented improved loading efficiencies, yet also 
demonstrated improved stability as well as prevention in drug expulsion during 
storage [30,33]. In the case of hydrophobic drugs, increased loading efficiency is 
achieved due to the inherent property of some drugs to better dissolve in the liquid 
than solid lipids, and it has already been demonstrated that increased solubility of the 
drug leads to higher loading efficiencies [34,35]. 
On the other hand, in the case of hydrophilic drugs, a lipid conjugation approach is 
followed, where the functional group of the drug (e.g., amine group) can be 
conjugated with the functional group (e.g., carboxylic acid group) of lipids like oleic 
acid, through carbodiimide or another type of chemistry. NLCs make use of the same 
lipids that mentioned in the previous section for SLNs as well as liquid lipids, some of 
which are almond oil, cetiol, corn oil, Mygliol® 812 N, oleic acid, olive oil, peanut 
oil, sesame oil[36], soybean oil, Speziol® EOL NF, Tegosoft® M, Tegosoft® P, 
Suppocire® NC, L-phosphatidyl choline (PC), soy lecithin, and Capmul® MCM C8. 
Similar are also the surfactants that are used for the NLCs fabrication, some of which 
are Cremophor® EL, Cremophor®RH, Eumulgin SML, Lutrol F68, Span® 85, Tego 
Care 450, Speziol® TPGS Pharma, Myrj 59, Tween® 20,Tween® 80, Pluronic® F68, 
N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethyl-ammonium chloride (DOTMA). The 
ratio between the solid lipid and the liquid lipid can range from 4:1 to 1:4, the 
surfactant concentration from 0.25 to 6 % (w/v), and the total lipid concentration from 
1 to 30 % (w/v).  
 
2.2. Fabrication methods 
SLNs and NLCs can be fabricated using a variety of methods each one of which has 
its own advantages and disadvantages. The most common technique that is robustly 
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used is the high-pressure homogenization technique (HPH). Due to its easiness in 
handling, its relatively low cost, and its ability of large-scale production, HPH became 
the most popular technique for the fabrication of lipid nanoparticles. The small size 
and the low polydispersity of the nanoparticles are two more characteristics that make 
this technique so attractive. HPH can be categorized into hot and cold HPH method. 
In the hot method, the lipid and the desired therapeutic, drug or nanoparticles, are 
mixed together above the melting temperature of the lipid and after the preparation of 
a pre-emulsion using an ultrasonic probe or a homogenizer or just stirring/vortexing, 
the lipid pre-emulsion is homogenized under high pressure. The high energies that are 
applied to the previously formed nano-emulsion results in sizes that span from the 
sub-micron range to as low as 40 nm [37]. 
On the other hand, in the cold homogenization method, after the lipid with or without 
the therapeutic molecule is melted, it is instantaneously cooled down using dry ice or 
liquid nitrogen, and milled creating sub-micrometer sized particles which are 
subsequently homogenized under high pressure, resulting in nanometer scale 
particles. Cold HPH was invented aiming at overcoming the limitations of hot HPH, 
one of which was the sensitivity of some therapeutic molecules above a certain 
temperature [38,39]. In both methods, the use of an organic solvent can be avoided 
making this technique also environmental friendly. 
It has to be noted, that HPH can be used to decrease the size of lipid nanoparticles 
already formed by other methods, but in this case, a high percentage of smaller 
nanoparticles or drugs that have already been encapsulated in the lipid core will be 
released. 
Two other methods that make use of high energies to reduce the particle size is the 
high-speed/shear homogenization technique (HSHT) and the emulsification-
ultrasonication technique (EUT) [30,31]. These approaches are more versatile than 
HPH and the size range, as well as the polydispersity of the particles, depends on the 
amount of energy that is given to the system. Low energies result not only in high 
polydispersity and sub-micron sized particles, but also to lower short and long-term 
stability. Increasing the amount of energy, the size and the polydispersity are reduced, 
and the stability is increased. In certain cases, a combination of these techniques is 
applied in order to obtain nano-sized particles. It is noteworthy, that the size and the 
polydispersity do not only depend on the energy applied to the synthesis of these 
nanoparticles, but also on the type of the solid lipids, the liquid lipids and the 
surfactants that are used, since steric hindrances due to functional groups or the length 
of the chain and crystallization parameters are different among materials. An 
advantage of this method is that lower amount of lipids, surfactants, and solvent 
volumes can be used in contrast to HPH, that requires a minimum volume of 1-2 ml. 
Another technique used for the synthesis of lipid nanostructures is the solvent 
emulsification/evaporation method (SEEM). This strategy is based on the oil-in-water 
(O/W) emulsion approach that is robustly used for the synthesis of polymeric 
nanoparticles and microparticles like poly(lactide-co-glycolide) particles [40 42]. In 
this technique, the solid and/or the liquid lipid are dissolved into a small amount of 
organic solvent, immiscible in water, and then they are added to a solution containing 
the surfactant at a ratio of maximum 10%. The mixed solutions are stirred or 
homogenized in high speeds, or they are ultrasonicated for a few minutes, aiming at 
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creating an emulsion. Depending on conditions used in each method, various sizes of 
nano- and/or microparticles can be obtained. After the emulsification process, the 
emulsion is left under mild stirring to evaporate the organic solvent, which leads to 
the hardening/stabilization of the particles [37,43 45]. Compared to the previously 
mentioned techniques, SEEM does not make use of high temperature, yet it owns the 
disadvantage of using toxic organic solvents. 
In the case of hydrophilic drugs, a double emulsification method can be used. In this 
case, the hydrophilic molecules are entrapped in dynamic nano- and/or 
microstructures made by a water-in-oil emulsion (W/O), and, subsequently, this 
emulsion is mixed with an excess of a water-based surfactant solution and emulsified 
again creating a water-in-oil-in-water (W/O/W) emulsion. Again, the double emulsion 
is mildly stirred for a few hours to evaporate the solvent. 
The same rationale for the fabrication of nanoparticles is also followed by the solvent 
displacement method (SDM), but this time the organic solvent is slowly added in a 
water solution under agitation without the creation of the emulsion. The solution is 
agitated until the complete evaporation of the solvent. Using the SDM method 
nanocapsules are fabricated. In contrast to the NLCs fabricated with the emulsion 
method, these nanocapsules are less stable and a leak of the therapeutic molecule is 
very common [24,31,42 44]. In order to increase the stability and to avoid drug 
leakage, the capsules are sprayed-dried or freeze-dried. In both cases, the stability 
increases but aggregations cannot be avoided. Spray-drying is an alternative method 
to freeze-drying but it is not used in extent due to the high temperatures and energies 
that are needed for the fabrication of particles [30,51,52]. 
The use of supercritical fluids for the fabrication of SLNs & NLCs is another method 
that is used for the preparation of these nanostructures. An emulsion is once more 
created; however, in this case, the organic solvent is removed with the help of a 
supercritical fluid, usually CO2. The supercritical fluid technology (SFT) is more 
energy efficient compared to HPH since it does not make use of the high pressures of 
HPH. In addition, by using the supercritical fluid technology the use of solvents is 
avoided and the nanostructures are obtained in dry powder, rendering unnecessary a 
further step of freeze-drying for the stabilization of the nanostructures. Although SFT 
presents many advantages, until today it has been used mostly for the synthesis of 
SLNs and not for NLCs [53,54]. A method that has been extensively used for the 
synthesis of polymeric nanoparticles but not so much for lipid nanoparticles is the 
fatty acid coacervation technique. In this approach, the alkaline salts of fatty acids 
coacervate due to proton exchange between the acid solution and the emulsifier, as the 
pH is lowering. The advantage of this technique is its easiness but a great 
disadvantage is the size of the formulated particles [55]. 
 
2.3. Nanostructures for the treatment of brain diseases 
Up to date, the synthesis of nanoparticles for the treatment of brain diseases has been 
very challenging due to the particularity of delivering therapeutics to the CNS. 
Numerous delivery strategies have been applied aiming at the fabrication of a delivery 
system that will combine specific characteristics like high loading efficiency, 
biocompatibility, and stealth features, but the most important characteristic would be 
the crossing through the BBB. Thus, inorganic and organic nanoparticles, 
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functionalized with targeting groups and/or coated with external layers of various 
biomimetic materials have been studied for this purpose. The most important 
nanostructures that have been studied for the delivery of therapeutics in the CNS are 
lipid-based structures like liposomes, SLNs and NLCs, lipoplexes, lipoproteins, 
polymeric nanoparticles, polymeric micelles, dendrimers, and inorganic nanoparticles 
including iron oxide, ceria, gold and quantum dots. Each of these systems owns its 
advantages and disadvantages, and in the next paragraph, we will try to briefly 
describe them. An overall description of the nanostructures that are used for the 
delivery of therapeutics to the CNS and their main advantages and disadvantages are 
given in Table 1. 
 
2.3.1. Polymer-based nanostructures 
 
Polymer-based nanostructures are used robustly in the biomedical field due to their 
versatility in synthesis and functionalization. The synthetic procedures allow their 
controlled size and shape as well as their loading ability. These polymeric 
nanostructures can be functionalized with desired ligands in order to target specific 
disease areas and depending on the monomers that are used for their fabrication, these 
nanomaterials have the ability to respond to physical/external (alternating magnetic 
field, light, electric current, ultrasound) [56 59] or biological/internal (enzymes, pH, 
reactive oxygen species - ROS -) stimuli [42,60 65]. The polymeric nanostructures 
are the first choice of researchers for the delivery of therapeutic molecules (e.g., 
drugs, enzymes, genes, DNA, inorganic nanoparticles), and their therapeutic, as well 
as their diagnostic nature, has been studied extensively. From all the synthesized 
nanostructures those ones that are mostly used for the treatment of brain diseases are 
polymeric micelles, polymeric nanoparticles, and dendrimers. 
 
Polymeric micelles 
Polymeric micelles are created by the self-assembly of amphiphilic molecules in 
water above a critical concentration which is called critical micelle concentration. The 
hydrophobic head creates the core where hydrophobic drugs can be encapsulated 
while the hydrophilic tale creates the shell which is responsible for the stability of 
these structures and their prolonged circulation times in vivo. The micelle size is 
comprised within the range 10-100 nm and their dynamic loading ranges from 20 to 
30%. Micelles are stable structures that provide controlled and sustained release and 
can be modified in a way that renders them responsive to external or internal stimuli. 
Micelles are preferred as a therapeutic vehicle for the treatment of CNS diseases and 
especially brain cancer because they have the inherent ability to penetrate the BBB 
and penetrate at the tumor site [66 69]. 
 
Polymeric nanoparticles 
Polymeric nanoparticles have similar characteristics to micelles concerning their 
loading efficiency, functionalization versatility, and responsiveness to biological or 
physical stimuli. The size of the nanoparticles ranges usually from a few nanometers 
to a few hundreds of nanometers, but for brain applications the preferable size is 
usually below 200 nm. Polymeric nanoparticles for medical applications are designed 
in order to be biodegradable and the usual polymers that are used in this kind of 
applications are poly- -caprolactone, polylactides, polyglycolides and their 
combination poly(lactide-co-glycolide). Although these materials are FDA-approved, 
their low solubility and their degradation in acidic by-products are considered serious 
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limitations for their use in brain diseases. Moreover, the use of organic solvents for 
the preparation of the majority of these nanoparticles is one more drawback that may 
cause increased toxicity issues [66,68,70 75]. 
 
Dendrimers 
Dendrimers comprise a class of polymeric nanostructures with well-defined 
architecture, high versatility in functionalization and internal cavities that allow the 
high encapsulation of drugs, genes, nucleic acids and other therapeutic agents. 
Dendrimers have been used as drug delivery systems due to their inherent ability to 
cross the BBB as well as the membranes of cells. Loading of dendrimers can be 
achieved either by encapsulation due to electrostatic interactions or by conjugation. In 
addition, the development of pH-sensitive dendrimers made possible the controlled 
release of encapsulated substances in diseased areas where the pH is acidic. 
Dendrimers like polyamidoamine (PAMAM) have been mostly used for cancer 
 
sclerosis and ischemic stroke have also been developed. Dendrimers, as polymeric 
structures, share the advantages and disadvantages of polymers but the main 
drawbacks that prohibit their robust use are the difficulties in scale-up and their 
inherent toxicity [76 80]. 
 
2.3.2. Inorganic nanoparticles 
The main advantage in the use of inorganic nanoparticles except for their small size it 
is also their multi-functionality. Nanoparticles like ceria, iron oxide, gold, and 
inorganic quantum dots have been used robustly not only due to their therapeutic 
characteristics, yet also due to their imaging capabilities. Many of these nanoparticles 
combine both therapeutic and diagnostic ability, falling under the category of 
biocompatibility compared to the above-mentioned systems [81 88]. 
 
2.3.3. Lipid-based nanostructures 
Liposomes 
As we mentioned before, liposomes are spherical vesicles that consist of one or more 
phospholipid bilayers. These unilamellar structures of a size range that span from 10 
to1000 nm are the predecessors of SLNs & NLCs and comprise the first generation of 
lipid nanostructures that were used for parenteral drug delivery. Some of the main 
advantages of liposomes are their high loading efficiency, their low toxicity, and their 
low antigenicity, while some of their disadvantages include low stability, difficulties 
in scale-up, fast clearance from the RES and a complex method of fabrication. 
Although the surface modification of liposomes (PEG coating), and the 
functionalization of their surface (antibodies, peptides, and aptamers) increases their 
circulation time, structural stability, and therapeutic ability, this is not enough to make 
these nanostructures attractive for industrial scale fabrication [23,67,68]. 
 
Lipoplexes 
The self-assembly of liposomes with nucleic acids through electrostatic interactions 
results into multi lamellar lipoplexes with positively charged lipid bilayers, separated 
by the negatively charged nucleic acids. Since lipoplexes are created from liposomes, 
they share the same advantages and disadvantages that were described above, but also 
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they present one more disadvantage which is the high affinity of the polycation 
towards the bound nucleic acid that reduces transfection once inside the cell. 
Lipoplexes have been used for various brain diseases and more information can be 
found in the cited literature [89 95]. 
 
Lipoproteins 
Lipoproteins are natural nanoparticles that are found inside the human body and their 
main role is the transportation of lipids (e.g., cholesterol), proteins, enzymes, and 
microRNAs. Lipoproteins have been used as an alternative approach, either alone or 
in combination with other nanoparticles (e.g., albumin, PEG-PLGA), for the treatment 
of various diseases including diseases of the CNS, and in principle, their advantages 
and disadvantages fall under the same category as the ones of liposomes [68,96 100]. 
 
SLNs/NLCs 
Solid lipid nanoparticles and nanostructured lipid carriers combine most of the 
advantages of the above-mentioned carriers, without being restricted by their 
limitations. One of their advantages that share with the polymeric nanoparticles is 
their small size, that allows them to easily flow in the blood stream without being 
uptaken by macrophages. One more characteristic that enhances the stealth ability of 
these nanoparticles against macrophages is the fact that they are made from natural 
materials and/or a combination of natural lipids, rendering them more biocompatible 
 Both polymeric nanoparticles and 
SLNs/NLCs can be functionalized with numerous targeting agents like peptides and 
antibodies, but in certain cases complex chemical reactions are needed for the 
functionalization of the polymer-based nanostructures compared to the lipid-ones. 
One great disadvantage of the polymeric nanoparticles is the burst release of 
encapsulated therapeutic molecules and their disability of long-term release. In order 
to achieve a long-term release an extra functionalization/modification is sometimes 
applied. These disadvantages are not found in the SLNs/NLCs due to their inherent 
ability of controlled release of various molecules (antioxidants, enzymes, therapeutic 
agents, etc.) for long periods of time. Release of encapsulated molecules is often 
realized due to the biodegradation of the therapeutic nanocapsule. This biodegradation 
often leads to increased toxicity when polymeric nanoparticles are used, a 
phenomenon that can be avoided when using SLNs/NLCs due to the fact that these 
nanoparticles are made from natural-based lipids that do not affect the 
extracellular/intracellular environment after their degradation. The fabrication 
procedure, where no need of organic solvents is necessary if compared to the 
fabrication of the polymeric structures and which allows reproducibility and high-
scale production, the high biocompatibility as mentioned previously, and finally the 
low immunogenicity that the lipid-based nanostructures present, allow them to be 
rendered as the best candidates for targeting diseases of the central nervous system. 
Although this type of nanoparticles demonstrates all of these advantages, it is also 
characterized by low encapsulation efficiencies which probably is one of the basic 
limitations that to date has not allowed its mass production and exploitation from the 
numerous companies within the biomedical field [31,66 68]. 
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3. Brain diseases and the role of BBB 
3.1. Blood Brain Barrier 
 
BBB is a highly selective barrier that plays a pivotal role to the homeostasis of the 
brain by regulating the passage of various substances between blood flow and CNS. 
BBB is part of a bigger structure called neurovascular unit (NVU), that exists along 
all brain capillaries, and is composed of endothelial cells (EC), pericytes, vascular 
smooth muscle cells (vSMC), neurons, astrocytes and perivascular macrophages 
[101]. Except the brain capillaries, there are also peripheral capillaries, the main 
difference of which lies to the lack of fenestration and intercellular pores, due to the 
presence of inter-endothelial tight and adherens junctions, limiting the transport via 
paracellular pathways. The main molecular components of tight junctions are zonula 
occludens proteins (ZO-1,2,3) claudins, occludin and cingulin, while the main 
components of adherens junctions are cadherins (Figure 2) [101]. Molecules like 
proteins, enzymes and nutrients can travel in and out of the CNS through different 
pathways. In the next paragraphs, the most important neurological diseases will be 
briefly analyzed, pointing out their molecular basis, their current limitations and their 
future perspectives concerning their treatment. The brief description that will follow is 
intended to give the reader a general view of the major CNS pathologies and does not 
have the claim of analyzing in detail each disease. For further details, the readers are 
advised to check the works cited at the end of the review. 
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3.2. Brain cancer 
 
Brain tumors can be divided in two macro groups: primary brain tumors which 
originate from brain tissues, and secondary brain tumors that are the result of the 
metastatic spreading of cancer cells, originated in other regions. Primary brain tumors 
are in turn classified into gliomas, central nervous system lymphomas (both of which 
originates from brain parenchyma and are the most frequent type of brain tumors), 
meningiomas and pituitary adenomas, that are extraparenchymatous tumors [102]. 
Gliomas are primary tumor that can originate from neural stem cells, progenitor cells, 
or from de-di erentiated mature neural cells transformed into cancer stem cells. They 
are classified on the basis of both their origins in astrocytomas, oligodendroglioma 
and mixed oligoastrocytoma, and on the basis of their aggressiveness in grades 
ranging from 2 to 4. Currently, the most used treatments known for brain tumors 
involve the use of surgical approaches and/or radiotherapy, that not only present a 
large amount of risk for the patient, but are also unable to efficiently treat more 
aggressive form of gliomas [103]. Finally, pharmacological treatments should be able 
not only to target cancer cells, yet also to destroy brain tumor stem cells in order to 
prevent a repopulation effect and to prevent all the processes involved in tumor 
metastatic spreading, including angiogenesis and cell extravasation. In Figure 3 the 
cellular mechanisms involved in brain cancer and other CNS diseases are presented. 
 
3.3. Ischemic Stroke 
 
The term stroke is 
origin with sudden (within seconds) or at least rapid (within hours) occurrence of 
symptoms and signs  
[104]. Stroke is divided in ischemic, in which blood supply to the brain is interrupted, 
and hemorrhagic. Ischemic stroke is again divided on the basis of its cause into 
thrombotic stroke when the cause is an artery thrombus, and in embolic stroke when 
the cause is the presence of emboli [105]. In both cases the interruption of blood flow 
to the brain cells causes imbalances of pH, glucose, oxygen, and other nutrient levels, 
leading to cell death. Currently, the only pharmacological treatment available and 
approved by FDA for ischemic stroke is the recombinant tissue plasminogen activator 
(r-tPA), which elicits a thrombolytic action by breaking blood clotting and restoring 
interrupted blood flow. 
 
3.4.  
 
PD is mainly caused by the neuro-degeneration of the dopaminergic neurons in the 
substantia nigra pars compacta, which is a basal ganglia structure involved in reward 
and movement control. The main symptoms of the disease are tremor, bradykinesia, 
rigidity, and postural instability. The disease evolves with a progressive loss of 
movement control that leads to severe respiratory and gastro-intestinal complications, 
 [106]. To date, the molecular basis of PD is still 
largely unknown. Currently there are no treatments for PD able to fully cure the 
disease. All the existent approaches are symptomatic treatments that try either to 
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restore dopamine levels or to ameliorate movement impairments. The most used 
pharmacological treatment for PD is still levodopa. 
 
3.5.  
 
AD is one of the most common forms of dementia, with more than 24 million cases 
worldwide [107]. This disease is characterized by decreased cognitive and physical 
functions and loss of memory, and it eventually leads to th
neuronal cell loss. The disease can manifest itself in the form of familiar AD, usually 
due to genetically causes, or in the form of sporadic AD caused by environmental 
factors. The principal areas of the brain affected by AD are neocortex, primarily 
involved in the processing of sensory information, and limbic system that plays an 
important role in the control of emotion, instinctive behavior, learning, and short-
memory. The basis of the disease is still largely unknown, but its main hallmark is the 
 a plaque. 
Several forms of familiar AD have been related to the presence of genetic mutations 
 a higher ratio of accumulation of 
oligomers, while disruption of clearance system due to genetic causes or 
environmental factors has been observed in sporadic form of AD. Currently, all the 
treatments for AD are only able to ameliorate symptoms but cannot lead to the 
regression of the disease or to its complete cure. Although many therapeutic 
molecules for the treatment of AD have been proposed, the development of specific 
drugs able not only to cross the BBB, yet also to inhibit the neurodegeneration and to 
heal damaged neurons, is still an open challenge. 
 
3.6. Multiple sclerosis 
 
The term Multiple sclerosis (MS) refers to a progressive and chronic disease 
involving the immune-mediated demyelination of the CNS white matter, involving 
visual neuron, basal ganglia, brain stem, and spinal cord [108]. Current treatments of 
the MS can be classified into symptomatic, that try to ameliorate symptoms of the 
disease, and effective treatment targeted to alter disease progress. A recent work by 
Dolati et al. [108] summarizes the current disease-modifying therapies for MS, most 
of which act by interfering with B and T cells activity, and reducing BBB 
disruption.Therefore, the development of carriers able to cross BBB and to 
specifically target immune cells is a priority in order to obtain more specific 
treatments with minimal side effects. 
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Figure 3. Representation of the main diseases affecting the central nervous system and of the involved 
; ; C) primary brain cancer; D) 
ischemic stroke; E) Multiple sclerosis. 
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4. Brain-targeting SLNs and NLCs for CNS diseases 
4.1. SLNs and NLCs in brain cancer 
 
Solid lipid nanoparticles and nanostructured lipid carriers have been used for the 
treatment of various brain diseases and mostly for brain cancer, due to their attractive 
properties. One of the studies presented in the last seven years was related to the 
synthesis of cationic solid lipid nanoparticles (CASLNs) which were functionalized 
with an anti-EGFR receptor aiming at targeting malignant glioblastoma cells [109]. 
The authors used the microemulsion method (MEM) to prepare cationic SLNs, and 
they demonstrated that the entrapment efficiency of carmustine (CRN) was related to 
the concentration of cationic surfactants that they were using, and that the release 
profile was dependent on the concentration of the cacao butter that it was used. 
Studies on the U87 cell line demonstrated an effective delivery and antiproliferative 
properties while studies in human brain microvascular endothelial cells demonstrated 
the enhanced viability and a decrease in the expression of tumor necrosis factor 
(TNF)-  
The same authors, in a follow-up work, have studied a variety of lipids including 
palmitic acid (PA), cacao butter (CB), stearic acid (SA), Dynasan® 114, Compritol
® 
888 ATO (CA), cardiolipin, tripalmitin and behenic acid (BA), anticancer drugs 
including doxorubicin (DOX) and etoposide (ETP) and various targeting groups 
including aprotinin (Apr), anti-melanotransferrin (Anti-Mtf), folic acid (FA), p-
aminophenyl- -D-manno-pyranoside, serotonergic 1B receptor subtype antagonist 
(S1BRSA), 83-14 monoclonal antibody (8314Mab), anti-endothelial growth factor 
receptor (AEGFR), tamoxifen and lactoferrin. Depending on the lipids and on the 
surface functionalization the size ranged from 80 to 280 nm and the surface charge 
was either positive or negative and ranged from 14 to 40 mV and to -13 to -38 mV, 
respectively. The encapsulation efficiency also varied from 17 to 95%. All the in vitro 
studies were carried out using the same cell lines (HBMEC, human U87 malignant 
glioma, human astrocytes) and the results demonstrated that the SLNs were non-toxic, 
had antiproliferative effects, and could infiltrate the BBB suggesting their potential 
therapeutic use in the treatment of glioblastoma multiforme (GBM) [109 117]. A 
detailed description of the basic characteristics of each study can be found in Table 2. 
In another study, solid lipid nanoparticles comprised either by Compritol® or 
Precirol® were prepared using a combination of hot melt homogenization technique 
(HMHT) and ultrasonic homogenization technique (UHT) and they were loaded with 
a prototype anticancer drug named edelfosine (EDF). These nanoparticles, the size of 
which was a little higher than 100 nm, were able to easily accumulate in the brain 
tissue, something that was attributed to the interaction of the surfactant Tween® 80 
with P-glycoprotein (P-gp). These nanoparticles were tested in vitro in a C6 glioma 
cell line as well as in vivo in a C6 glioma xenograft tumor. The results showed an 
antiproliferative effect and a significant reduction in the tumor growth [118]. 
To overcome the stability problems and the low loading capacity of the SLNs, another 
group presented the fabrication of NLCs that were loaded with cytarabine (CRB), 
aiming at targeting meningeal leukemia. The NLCs had an average size of 
approximately 90 nm and they were coated using Tween® 80 aiming at overcoming 
the P-gp inhibition. The entrapment efficiency of these nanoparticles was found to be 
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approximately 50%, which was very high considering the hydrophilic nature of the 
encapsulated drug. The blank NLCs and the loaded NLCs (Cyt-NLCs) were 
characterized using differential scanning calorimetry (DSC) and X-ray diffraction 
analysis (XRD). The in vitro release profile of the Cyt-NLCs presented a fast release 
(ca. 16%) in the first hour but a slower and sustained release for the following 72 h 
(ca. 90%). Treatment of the EL-4 cell line with blank NLCs did not present any 
cytotoxic effects, while treatment with the loaded NLCs presented a dose-dependent 
cytotoxicity which was also higher compared to the treatment with the free drug 
[119]. 
The use of small interfering RNAs (siRNAs) is a promising strategy for the treatment 
of various diseases but due to their instability and their poor delivery into target 
tissues siRNAs are not robustly used. The use of encapsulated siRNAs in solid lipid 
nanoparticles was reported in the literature [120], as a way to overcome the 
limitations that siRNA presents and to enhance its therapeutic efficacy. In this study, 
low-density lipoprotein (LDL) was conjugated with a PEGylated c-Met (tyrosine-
protein kinase Met or hepatocyte growth factor receptor) siRNA aiming at forming 
spherical nanoparticles. The in vitro studies in U87MG demonstrated a decrease in 
cell proliferation and a down-regulation of the expression levels of c-Met. The in vivo 
experiments in a U87MG xenograft tumor demonstrated an enhanced accumulation of 
the SLNs to the brain tumor, a down-regulation again in c-Met levels, and also a 
tumor suppression rendering this nanoparticle a potential candidate for the treatment 
of glioblastoma multiforme. 
SLNs of cetyl palmitate (CP), stabilized with Tween® 60 or Tween® 80 were used for 
internalization studies, and the results demonstrated that the synthesized nanoparticles 
of a mean diameter of 200 nm and a surface charge of -20 mV were internalized by 
gliomas (A172, U251, U373 and U87 cell lines) in a higher amount than macrophages 
(THP1 cell line). The assessment of the cellular uptake mechanism was carried out 
using nanoparticles loaded with rhodamine 123 (R123), and it was found that the 
nanoparticles were internalized by a clathrin-dependent endocytic pathway [121]. A 
few months later, the same nanoparticles, prepared with a different technique and with 
a small modification in the used materials, were loaded with the drug camptothecin 
(CPT) aiming at increasing its therapeutic activity. In vitro studies demonstrated an 
increased uptake of the nanoparticles from porcine brain capillary endothelial cells 
(BCEC) compared to macrophages (RAW 264.7). In addition, cell viability of BCEC 
was decreased in CPT-loaded SLNs compared to free CPT. The in vivo studies in this 
work revealed the successful delivery of R123 to the brain [122]. A follow-up study 
using the same nanoparticles, but modified with 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), revealed that both loaded and unloaded nanoparticles have 
an orthorhombic sub-cell packing that is preserved in contact with the DMPC 
membrane that helps in the efficient release of CPT. In addition, biodistribution 
studies demonstrated that the concentration of the encapsulated CPT was higher in the 
serum and the brain compared to the free drug and that the loaded CPT could be 
detected in the brain even after 24 h, where the free drug could be detected only up to 
8 h [123]. 
A targeted approach of NLCs based on CP and three different fatty amines was also 
presented at the same time, and in this work, the NLCs were loaded with etoposide 
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and functionalized with an anti-transferrin receptor aiming to create a targeted 
delivery system for the treatment of myelogenous leukemia. The nanostructures were 
prepared by combining the emulsion-solvent evaporation method and the 
ultrasonication method, and the functionalization of the particles with transferrin (Trf) 
was carried out in two ways: using covalent conjugation and physical coating. The 
size of the particles ranged from 125 to 250 nm and their surface charge from +25 to 
+45 mV. The K562 cell line was used for the in vitro cytotoxicity studies using MTT, 
and flow cytometry was used for cell uptake investigation. The functionalization of 
the nanostructures with Trf decreased their surface charge and their loading 
efficiency, and also increased their size. Nevertheless, the loaded NLCs conjugated 
with Trf showed higher cellular uptake and enhanced antiproliferative effect with 
respect to the unconjugated ones [124]. 
A different approach was used from another group to fabricate lipid nanocapsules 
(LNC). These nanocapsules had a size of approximately 90 nm and a surface charge 
of +11 mV. The nanocapsules were functionalized with the L1 peptide and, in 
contrast to other published studies, they were not loaded with drugs, yet instead with a 
locked nucleic acid (LNA) aiming at silencing the oncogenic miR-21. The in vitro 
studies in the U87 malignant glioma (U87MG) cell line demonstrated a reduction of 
miR-21 expression, which resulted in an increased cell sensitivity after radiotherapy 
[125]. 
Curcumin is a well-known antioxidant, the therapeutic properties of which have been 
suggested for the treatment of brain cancer. Unfortunately, due to its low 
hydrophilicity, its delivery across the blood brain barrier is minimal. A study in which 
curcumin was loaded into lipid nanocapsules prepared by interfacial deposition of 
polymers was presented a few year back. Here, lipid nanostructures of approximately 
200 nm and a negative zeta potential have been fabricated and it has been 
demonstrated that curcumin had a sustain release profile for over 48 h. The in vitro 
studies in the U251MG cell line showed that the curcumin-loaded LNCs (C-LNC) 
were more cytotoxic compared to the free curcumin. Moreover, in vivo studies on rats 
bearing C6 gliomas presented a decrease in tumor size and malignancy, and 
prolonged the animal survival when they were treated with C-LNCs, in comparison to 
the animals that were treated with the same dose of the free drug [126]. 
Lipid nanocapsules were also used from another group, but this time the encapsulated 
therapeutic molecule was indomethacin. The results from these studies carried out in 
C6 and U138-MG glioma cell lines showed that the indomethacin-loaded lipid 
nanocapsules (IndOH-LNCs) reduced cell viability by inducing apoptotic cell death. 
Furthermore, an interesting finding of this study was that the IndOH-LNC did not 
affect the viability of human astrocytes suggesting the selectivity of these LNCs 
towards glioma cells. Moreover, it was shown that IndOH-LNC modulated the cell 
cycle dynamics and promoted the cell differentiation of glioblastoma cells [127]. 
The next published work presented the fabrication of solid lipid nanoparticles loaded 
with resveratrol (RVR). These nanostructures presented a size ca. -
potential of about -25 mV. The authors in this work showed that RVR-loaded 
nanoparticles had the same cytotoxic effect as the non-encapsulated drug and that the 
RVR concentration in the brain was higher (17.2800 ± 0.6344 mg/g) when the drug 
was encapsulated inside the SLNs, compared to the free drug (3.4500 ± 0.3961 mg/g). 
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It has to be noted that the nanoparticles were not functionalized with a targeting 
moiety, proving their inherent ability of passive targeting into the brain [128]. 
Another system based on lipid nanoparticles was presented almost at the same time, 
where SLNs were fabricated using the fatty acid coacervation technique (FACT). 
Doxorubicin was encapsulated inside these SLNs aiming at enhancing its permeation 
through an in vitro BBB model. The disadvantage of this technique is the large size of 
the fabricated nanoparticles wherein the specific case ranged from 278 to 1600 nm. 
Nevertheless, it was demonstrated that the permeation of doxorubicin through an 
hCMEC/D3 cell monolayer (BBB model) was higher when DOX was encapsulated 
inside the SLNs compared to the free DOX, and also that DOX-loaded SLNs did not 
affect the cytotoxicity in three types of glioblastoma cells (hCMEC/D3, primary 
human glioblastoma cells (CV17, 01010627), U87MG)[129].  
The fatty acid coacervation technique was used once more to fabricate spherical 
nanoparticles, of diameter 300-600 nm, loaded with paclitaxel (PTX). These 
nanoparticles had a positive surface charge (8-20 mV) and their loading efficiency 
spanned from 25 to 90%. The SLNs were able to penetrate an hCMEC/D3 cell 
monolayer which was used as a BBB model. From this study, it was concluded that 
even though stearyl amine positively charged nanoparticles gave the best results, the 
positive charge was not affecting so much the permeation ability. In addition, an 
increased toxicity towards glioblastoma cells was presented from the PTX-loaded 
SLNs [130]. 
Curcumin was used once more as an anticancer drug in another study, where the 
authors encapsulated the drug in NLCs (CRM-NLCs). The fabricated system had a 
size of 150 -potential of -20 mV and a 
loading efficiency ca. 90%. The loaded NLCs not only presented enhanced 
cytotoxicity towards the U373MG cell line, but they also presented higher 
accumulation to the brain (86201.0 ± 8182.1 ng/g after 120 min) compared to the free 
curcumin (54321.0 ± 2098.8 ng/g after 180 min) suggesting this drug delivery system 
as a potential candidate for the treatment of GBM [131]. 
Hyaluronic acid (HA) was used as another targeting approach for the treatment of 
GBM since it has the ability to bind to the CD44 receptor which is overexpressed in 
this type of cancer. The authors of this work fabricated lipid-based nanoparticles 
(LNP) loaded with polo-like kinase 1 (PLK1) siRNAs (siPLK1), and demonstrated an 
enhanced reduction in the expression of PLK1 mRNA that resulted in increased cell 
death. The fabricated HA-LNPs had a size of 100 nm, a slightly negative charge of -8 
mV and an entrapment efficiency of 80%. HA coating increased the permeability of 
the nanoparticles even under shear flow, and the in vivo studies in an orthotopic 
xenograft model showed reduced mRNA levels by more than 80% and a significantly 
prolonged survival of the treated mice. It is noteworthy that these results were beyond 
any published report in this model [132]. 
SLNs loaded with bevacizumab (BVZ) were reported elsewhere [133]. The 
nanoparticles were prepared using the coacervation technique, and even though their 
minimum size was 500nm, the in vitro results demonstrated that the BVZ-loaded 
SLNs had the ability to penetrate the hCMEC/D3 monolayer of cells and to increase 
the activity of BVZ by 100- to 200-fold compared to the free BVZ. 
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Temozolomide (TMZ) is one of the most robust drugs that are currently used for the 
treatment of brain cancers, and a published report demonstrated its therapeutic 
advantage when it is loaded inside NLCs [134]. In this work, TMZ was encapsulated 
along with DNA and their therapeutic efficacy was evaluated against U87MG cells. 
The fabricated NLCs had a size of 180 -potential of +23 mV, an encapsulation 
efficiency of 83% and a gene loading of 91%. In addition, in vivo studies 
demonstrated a high gene transfection and anti-tumor activity. In another report, the 
authors fabricated NLCs loaded with TMZ and functionalized with an arginine-
glycine-aspartic acid (RGD) peptide [135]. The nanostructures had a size of 120 nm, a 
positive surface charge of +28 mV and an encapsulation efficiency of 85%, and 
presented an inhibitory effect against U87MG glioma cell that renders them a 
promising strategy for the treatment of gliomatosis cerebri. 
An interesting study from the same group was published one year later, and reported 
the advantages and disadvantages among SLNs, NLCs and polymeric nanoparticles 
(PNPs) prepared by the solvent diffusion technique (SDT) for the delivery of TMZ to 
the brain [49]. All the nanoparticles had a size around 100 nm and an entrapment 
efficiency of 80%. The difference in these nanoparticles was in the surface charge: 
while the PNPs exhibited a high positive charge, the SLNs and NLCs instead a highly 
negative one. From all the above formulations the TMZ-loaded NLCs (TMZ-NLCs) 
displayed the best antitumor activity both in vitro against U87MG cell line and in vivo 
in a mice-bearing malignant glioma model. The same group after a while presented 
the fabrication of NLCs loaded with both TMZ and DNA (TMZ/DNA-NLCs). 
In another study, the therapeutic efficacy of SLNs and NLCs loaded with TMZ and 
vincristine (VCR) was evaluated [136]. The SLNs & NLCs were compared with 
SLNs and NLCs loaded only with TMZ (T-SLNs & T-NLCs). The in vitro and in vivo 
studies presented a better anti-tumor activity using the NLCs and also the co-delivery 
of the two encapsulated drugs (VT-SLNs & VT-NLCs) was better than the use of only 
TMZ. The inhibition rates for the T-SLNs, T-NLCs, VT-SLNs, and VT-NLCs were 
42.94%, 70.26%, 55.70% and 83.17%, respectively, while the inhibition rate for the 
free TMZ solution was 26.34%. 
NLCs loaded with curcumin (Cur-NLCs) were reported in a recent study [137]. The 
fabricated NLCs had a size of 210 nm and an encapsulation efficiency of 88%. The 
results showed that the IC50 value of Cur-NLCs was 75% lower than that of the free 
curcumin, proving the enhanced activity of the Cur-NLCs. Moreover, the 
encapsulation of curcumin prolonged its half-life and increased its levels in the blood 
by 6.4-folds. Further studies showed an enhanced efficiency of Cur-NLCs in mice 
bearing A172 xenografts with an inhibition ratio of 82.3% on tumor growth, and also 
showed that the inhibition effect was mostly due to apoptosis and not necrosis. 
The most recent study for the treatment of GBM that was reported [138] made use of 
PTX-loaded NLCs that were functionalized with Trf. In this report, different 
formulations of NLCs were fabricated and tested against U87MG cells. The NLCs 
had a size ca. 200 nm, a surface charge of +25.7 mV, an EE of 92% and a loading 
capacity of 5.38%. The above values were slightly decreased after the conjugation of 
the NLCs with Trf  (Tf-PTX-NLCs), but its cytotoxic effectiveness was increased 
compared to unconjugated NLCs. Finally, in vitro release profiles showed a slow and 
sustained release over a period of time. 
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The last reported study for the treatment of glioblastoma multiforme was presented a 
few months ago [139,140]. The authors of this study fabricated lipo-polymeric 
nanoparticles (LPNPs) by using a combination of C15 lipids, DSPE-epoxy-PEG 2000 
and polyethyleneimine (PEI) of molecular weight 600. The size of the nanoparticles 
spanned from 40 to 135 nm, depending on the ratio between the lipid segment and the 
PEI segment. The LPNPs were conjugated with an RNAi and targeted the brain 
tumor-initiating cells (BTICs), which have been reported to be responsible for therapy 
resistance, recurrence, and progression of diffuse gliomas. The delivery of the LPNPs 
in an in vivo established brain model was achieved using a convection-enhanced 
delivery method (CED) which it has to be noted that at this stage is under clinical 
trials. The results showed a significant extension of median survival in two patient-
derived BTIC xenograft mouse models of GBM. Another important finding of this 
study was that limited dosing is insufficient to overcome tumor growth despite a clear 
attenuation of malignant tumor growth. 
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4.2. SLNs and NLCs in ischemic stroke 
 
Even though ischemic stroke is one of the diseases with highest percentages of 
morbidity and mortality worldwide, the therapeutic solutions that are presented in the 
literature using SLNs and NLCs during the last seven years are very limited. One of 
the reasons may be the use of similar polymeric systems which give the advantage of 
more versatile surface functionalization compared to the lipid nanostructures. 
One of the studies that were presented seven years ago made use of the lipophilic drug 
vinpocetine (VIN), which is used for chronic cerebral vascular ischemia [141]. Its 
lipophilic character is responsible for its low bioavailability as well as its short half-
life. Aiming at overcoming these limitations, VIN loaded NLCs (VIN-NLCs) with a 
size from 100 to 200 nm, a slightly negative charge and an encapsulation efficiency of 
approximately 95% were fabricated. The results of this study demonstrated a 
sustained release profile with no burst release, as well as an increase of 322% in the 
bioavailability compared to the free drug. 
A few years after this study, other two scientific publications presented the enhanced 
therapeutic efficacy of VIN after its encapsulation. In the first study, different 
formulations of SLNs were prepared with the high shear/speed homogenization 
technique (HSHT) aiming at finding the optimum formulation for the loading and the 
release of VIN. The results of the best formulation showed an encapsulation 
efficiency of more than 83% and a sustained release profile for over 96 h indicating 
its potential use as a controlled delivery system [142]. In the second study, a different 
approach for the fabrication of VIN-NLCs was used. The authors of this work 
fabricated complexes of vinpocetine, cyclodextrin (CD), and tartaric acid (TA), that 
were encapsulated inside Compritol® ATO 888-based NLCs. The in vivo studies that 
were carried out in New Zealand rabbits demonstrated an enhanced oral 
bioavailability of 522% compared to the free VIN, and of 92% compared to VIN-
NLCs [143]. 
The antioxidant properties of curcumin were also used for the treatment of ischemic 
stroke according to one study that was published in 2013 [144]. Here, the authors 
compared the therapeutic effect of free curcumin and SLN-encapsulated curcumin, 
and the results showed an improvement of 90% in cognition and 52% inhibition of 
acetylcholinesterase levels. In addition, the levels of numerous enzymes including 
glutathione (GSH), superoxide dismutase (SOD), catalase, and others were 
significantly increased suggesting the therapeutic efficacy of the delivery system. 
One of the few targeted strategies for the treatment of ischemic strokes made use of 
PEGylated lipid nanoparticles (PLNs) that were loaded with 3-n-butylphthalide 
(NBP) and were conjugated with the FAS ligand antibody [145]. From the in vivo 
studies, it was shown that the PLNs accumulate in OX42 positive microglia cells in 
the ischemic region of a mouse model, and they improve the brain injury after 
ischemia in much lower dosages than the free NBP. 
The neuroprotective properties of encapsulated baicalin against ischemic stroke were 
used by two different groups. In the first study, where baicalin was encapsulated in 
SLNs -potential of -50 mV, the results 
showed a higher accumulation of the loaded baicalin in the cerebral cortex and in 
brain stem, compared to the unloaded drug, and an improved bioavailability and 
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stability [146]. A targeted approach using baicalin encapsulated in NLCs was 
presented three years later [147,148]. In this work, PEGylated cationic SLNs 
conjugated with an OX26 antibody, presenting similar encapsulation efficiency and 
smaller size compared to the previously reported work, were used. The authors, after 
fabricating and characterizing in detail their formulations, proceeded with the in vivo 
work. Their pharmacodynamic studies showed a reduction in the content of aspartic 
and glutamic acid and an increase in the concentrations of glycine, taurine, -
aminobutyric acid during ischemia-reperfusion. Furthermore, it was also shown that 
the bioavailability of baicalin in the cerebral spinal fluid of rats under the cerebral 
ischemia-reperfusion injury was higher, and that also its uptake into the brain was 
improved. 
Table 3 presents in detail the basic characteristics and properties of the lipid 
nanostructures that were used for the treatment of ischemic stroke. 
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4.3. SLNs and NLCs in  
 
to a 
progressive movement disorder. PD is not directly life threatening, but its symptoms 
significantly reduce the quality of life of people that live with this disease. To date, 
there is no real cure for PD but the therapeutic treatments reduce some of the patient 
symptoms. 
A few studies have been presented over the years for the treatment of PD, a number of 
which included the use various drugs encapsulated in SLNs and NLCs, including 
apomorphine (APO). In one of the studies [149], APO was encapsulated in three 
different formulations: SLNs, NLCs and lipid emulsions (LEs), and a comparative 
study of these formulations were carried out. Depending on the type of the 
nanostructure, the size, the surface charge, the encapsulation efficiency and the 
release profile were different, with the LEs to give the best results concerning the 
sustained release. On the other hand, in vivo real-time bioluminescence experiments 
on the brain of male Sprague-Dawley rats, using sulforhodamine B (SRB), 
demonstrated that NLCs could accumulate to selected brain regions compared to the 
other two formulations. 
Another study using the same drug was carried out aiming at assessing the feasibility 
of oral apomorphine delivery by using SLNs [150]. This study showed that emulsifier 
variations affect the physicochemical properties of the SLNs, that may influence their 
in vivo performance. In vivo experiments demonstrated that SLNs improved APO 
bioavailability and were able to deliver the drug to the brain striatum suggesting the 
potential use of the SLNs as a delivery system for APO through oral administration. 
A different strategy using APO as the main drug was published from the same group 
two years later [151]. In this work, the authors encapsulated two APO-based 
prodrugs, diacetyl apomorphine (DAA) and diisobutyryl apomorphine (DIA) inside 
NLCs and they assessed their physicochemical properties. The release studies 
revealed a slower release profile for the DIA, and the hydrolysis study indicated that 
the prodrugs underwent bioconversion in plasma and brain extract. The hemolysis and 
the LDH release revealed a good tolerance by erythrocytes and neutrophils. Finally, 
the authors used PEGylated and non-PEGylated NLCs, P-NLCs, and N-NLCs 
respectively, the bioimaging results of which showed a greater extent of accumulation 
of P-NLCs compared to N-NLCs in the brain. 
The encapsulation of ropinirole (RPN), a commercial drug that is used for the 
treatment of PD, in a hybrid polymer-lipid nanoparticles (PLNs) is another strategy 
that has been reported in the literature [152]. The nanoparticles in this study were 
fabricated aiming at delivering RPN through the intranasal route, and it was found 
that the hybrid nanoparticles presented good mucoadhesive properties without 
significantly damaging the nasal mucosa. A comparative study between the PLNs and 
a commercial formulation demonstrated similar experimental results, suggesting the 
superiority of the PLNs since less amount of drug was needed in order to have the 
same therapeutic effect as the commercial drug. 
RPN was once more used as the encapsulated substance inside NLCs in a study the 
main goal of which was to study the effect of surface charge on the brain via the nasal 
route [153]. Anionic and cationic NLCs with an absolute surface charge of 34 mV 
were fabricated, the former of which caused mild inflammation to the nasal 
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epithelium, while the latter caused the destruction of the lining mucosal nasal 
epithelium. In addition, even though a higher accumulation in the brain was observed 
for the cationic NLCs, the anionic presented the highest drug targeting efficiency. 
Gelatin nanostructured lipid carriers (GNLs) are another type of hybrid lipid 
nanoparticles that have been reported for the treatment of PD [154]. The authors of 
this work fabricated hybrid phospholipid-based gelatin nanoparticles and loaded them 
with a basic fibroblast growth factor (bFGF), aiming at the delivery of this growth 
factor into the brain, through the intranasal route. The size of the nanoparticles was 
approximately 140 nm with a surface charge of -38 mV. The in vivo studies in a rat 
model of hemiparkinsonism revealed that the GNLs could successfully deliver the 
bFGF in olfactory bulb and striatum, yet not in prefrontal cortex or hippocampus. 
A detailed description of the basic characteristics and properties of the SLNs and 
NLCs that are used for the treatment of PD is given in Table 4. 
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4.4. SLNs and NLCs in  
 
Alz  is characterized by memory loss and other cognitive inabilities, 
that render the patients incapable of dealing with daily tasks. The progression of the 
disease varies depending on the patient, but ultimately leads to death with a mean life 
expectancy from three to nine years. Numerous studies have been reported for treating 
AD, and in this section we are going to focus on the studies that make use of the 
various lipid nanoparticles. 
One of the drugs that have been used for the treatment of AD is Huperzine A (HupA). 
HupA is cholinergic that acts as a cognitive transmitter and can potentially help AD 
patients. Two studies that made use of encapsulated HupA in SLNs and NLCs have 
been presented during the last seven years. In the first study [155], the authors 
prepared CP-based NLCs loaded with HupA, and they studied their morphological 
characteristics as well as their physicochemical properties. The size of the NLCs was 
120 nm and their surface charge was -22.93 mV. The NLCs presented a good loading 
efficiency (89.18%), although their loading capacity was not so high (1.46%). The in 
vitro release profiles showed a controlled drug release for up to 96 h. In the second 
reported study [156], the authors encapsulated HupA in three different formulations 
aiming at finding the optimum strategy for its transdermal delivery. The three 
formulations were microemulsions (MEMs), SLNs and NLCs. The sizes of these 
formulations were close to the ones of the NLCs in the previously reported study, but 
their surface charge was different depending on the method. The in vivo studies, 
carried out on male Swiss Albino mice, demonstrated that the MEMs exhibited the 
2) cumulative amount of drug permeation followed by 
the NLCs and SLNs. In addition, skin irritation experiments for 48 h using gels 
demonstrated that the latter is safe for skin use. 
Quercetin (QRT) is a polyphenol that belongs to the group of flavonoids. As a 
polyphenol, QRT exhibits antioxidant properties and has been used for the treatment 
of various diseases like cancer and atherosclerosis. The therapeutic effect of 
encapsulated QRT inside SLNs for the treatment of AD was reported a few years back 
[157]. The authors in this study fabricated QRT-loaded SLNs based on compritol, 
aiming at the fabrication of a system that could penetrate the BBB after intravenous 
administration. The size of the fabricated SLNs was less than 200 nm, they exhibited 
a positive surface charge of 22 mV and a good encapsulation efficiency of 85.73%. 
The in vivo data showed that the rats treated with QRT-loaded SLNs exhibited better 
memory-retention vis-à-vis than the rats that were treated only with pure QRT. 
One of the characteristics of AD are the irregular amounts of the neurotoxic beta-
de which undergoes aggregation and forms oligomers, fibrils and 
plaques; a possible therapeutic approach is the treatment of these oligomers. A 
research 
that made use of SLNs in order to fabricate a targeted delivery system for AD [158]. 
The authors fabricated two types of nanoparticles, liposomes, and SLNs, and made a 
comparative study of their physicochemical properties. The immunostaining studies 
that were carried out demonstrated that anionic phospholipids are suitable for 
SLNs comprised of stearic acid, 
Phospholipon 90G, sodium taurocholate and phosphatidic acid (PA) or cardiolipin 
1-42 aggregates, while the plain SLNs could not. The 
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authors also observed that the PA/CL modified nanoparticles did not bind to bovine 
serum albumin (BSA). Unfortunately, this work was not supported from in vivo 
studies. 
Partial targeting of the brain due to the Tween® 80 emulsifier, that was used for the 
fabrication of SLNs loaded with piperine (PPR), was reported by another group [159]. 
In this work, the authors assessed the behavioral and the biochemical effect of their 
nanoparticles in an experimentally induced AD model. The SLNs reduced the values 
of SOD and the values in immobility while increasing the acetylcholinesterase values. 
The synthesized pharmaceutical formulation was compared with the commercial drug 
donepezil and exhibited better results in the treatment of AD. In this study, the 
minimum therapeutic efficacy of PPR was found at a concentration of 2 mg/kg body 
weight of rats. 
Low-density lipoprotein (LDL) mimicking SLNs were reported as another form of 
brain targeting nanoparticles [160]. In this work, SLNs made of the same lipids as 
LDL were loaded with curcumin and their surface was functionalized with the protein 
lactoferrin (Lf) (Lf-mNLCs). The in vitro studies in brain capillary endothelial cells 
(BCECs) showed an increased uptake (about 1.5 folds) of the Lf-mNLCs compared to 
the plain NLCs, with the result being better in the ex vivo studies, where the 
accumulation at the BBB of penetrating Lf-mNLCs was about 3 times higher than the 
plain ones. Finally, it was proved from the pharmacodynamic studies that AD 
progression could be controlled. 
SLNs aiming at the treatment of AD were also reported by other groups. Each of these 
groups made use of various lipid matrices and used different drugs. The most 
important studies were those ones that made use of lipoyl-memantine (LA-MEM) 
[161], sesamol, and chrysin. In the study where LA-MEM was used, the authors 
synthesized and fully characterized LA-MEM loaded SLNs. The results demonstrated 
that the particles were stable in both simulated gastric fluid (SGF) and simulated 
intestinal fluid (SIF), and that presented a controlled release profile. 
A more detailed study was presented by the group that synthesized sesamol-loaded 
SLNs [162]. The in vivo studies were performed on an experimental model of AD, 
where rats were injected intracerebroventricularly with the glucosamine-nitrosourea 
compound streptozotocin (ICV-STZ rats), that produces reduced cognition and 
. The 
results demonstrated that the chronic treatment with free sesamol and with sesamol-
loaded SLNs in a dose-dependent manner could effectively restore cognitive deficits 
and help with the mitigation of nitro-dative stress and cytokine release. 
The last reported publication for the treatment of AD presented the use of chrysin as a 
model drug inside SLNs [163]. The loaded nanoparticles were able to protect against 
neurona 25 35. Furthermore, the 
therapeutic effect of the nanoparticles was demonstrated by the reduction of all the 
antioxidant and non-antioxidant enzymes in the hippocampus, as well as from the 
increase in the lipid peroxidation and of the acetylcholine esterase. 
A detailed description of the basic characteristics and properties of the SLNs and 
NLCs that are proposed for the treatment of AD is given in Table 4. 
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4.5. SLNs and NLCs in multiple sclerosis 
 
Even though many reports in the synthesis and characterization of SLNs and NLCs 
have been published the last seven years for the treatment of various CNS diseases, 
two of them have been reported for the treatment of multiple sclerosis. 
In the first study, the synthesis of SLNs loaded with the drug riluzole (RLZ) is 
reported [164]. The synthesized particles had a size less than 90 nm and a negative 
surface charge of approximately -46 mV which was responsible for the high stability 
of the dispersion. The in vivo studies in adult Sprague-Dawley rats demonstrated that 
the concentration of the encapsulated RLZ was higher in the brain and lower in other 
body organs compared to the free RLZ, suggesting that the SLNs were able to 
penetrate the BBB and to enhance the delivery of RLZ in the brain. 
In the second reported study, SLNs were used once again but in this case loaded with 
methylprednisolone (MEP) and functionalized with two glycoprotein antigens, anti-
contactin 2 (anti-Cntn2) and anti-neurofascin (anti-Nfasc). Even though the SLNs 
presented good release profiles and no toxic effects when they were tested against 
U87MG cells, it was interesting the fact that the plain SLNs exhibited better 
penetration ability to the BBB compared to the PEGylated and functionalized anti-
Cntn2/anti-Nfasc SLNs. 
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4.6. SLNs and NLCs in for treating other diseases of the CNS 
 
In the previous paragraphs, a detailed description of the reported SLNs and NLCs 
formulations that were used during the last seven years for the treatment of the main 
CNS diseases has been performed. Although a great number of publications that 
covered many of the CNS diseases were presented, there is still a significant amount 
of scientific studies that deal with other CNS diseases. Since the focus of this review 
is on the use of SLNs and NLCs for the treatment of the main CNS diseases, we are 
not going to describe in detail these studies. Nevertheless, due to the significance of 
these scientific studies, we briefly describe in Table 7 the basic properties, the basic 
characteristics and the therapeutic targets of the fabricated systems that were used in 
the last seven years, hoping to help the reader to understand the extent of the 
capabilities of the described lipid nano-formulations. 
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5. Conclusion & Future Perspectives 
Medicinal formulations fabricated owing to nanotechnological development have 
been extensively used in the biomedical field in the last decade. These formulations 
can be in the form of inorganic or organic nanoparticles, hydrogels, spherical or 
worm-like micelles, dendrimers, nanorods, nanotubes and others, and can comprise 
several different materials. The combination of various materials is what gives these 
nanostructures their versatile properties, and what makes them so attractive in 
nanomedicine. 
To date, the majority of the nanostructures that have been used for the treatment of 
various diseases are made of synthetic polymers like PLGA. Although many studies 
that make use of polymeric nanoparticles have been presented, and although many of 
the products of these studies have been commercialized, there is still a great need of 
finding therapies for untreatable diseases like cancer, HIV, ischemic stroke, 
 myocardial infarction, 
atherosclerosis, and others. The polymeric nanostructures demonstrate great 
advantages including versatility in functionalization, controllable sizes and shapes, 
high concentrations of encapsulated substance and ability to be used in the theranostic 
field, but they also present disadvantages, the most important of which are difficulties 
in scaling up, use of organic solvents during their fabrication, biocompatibility, 
cytotoxicity and immunogenicity. Numerous fabrication and functionalization 
techniques have been developed in order to overcome these disadvantages, and to a 
certain extend these techniques have been successful, but without resolving 
completely these problems. Thus, new nanostructures had to be developed aiming at 
overcoming the limitations of these systems. 
Lipid-based formulations can be characterized as the next generation of drug delivery 
systems, since they share most of the advantages of the polymeric nanostructures 
without their harmful disadvantages. These lipid-based formulations, the most studied 
of which are solid lipid nanoparticles and nanostructured lipid carriers, are gaining 
more and more space in the biomedical field for the treatment of numerous diseases, 
and especially brain cancer and neurodegenerative diseases. Their small size and their 
inherent ability to cross the BBB, even without any surface functionalization, make 
them excellent candidates for the treatment of various CNS diseases. 
In this review, we tried to give an insight of the most important brain diseases and the 
reported studies that make use of SLNs and NLCs for their treatment, during the last 
seven years. We have described a variety of fabrication and characterization 
techniques for the synthesis of these nanostructures and we gave a detailed description 
of their use in the CNS. It is obvious from all the reported studies that SLNs and 
NLCs have been advancing over the years. New fabrication and functionalization 
techniques have been applied, allowing the SLNs and NLCs to successfully deliver 
their therapeutic cargo to specific tissues in a controlled and sustained manner. In 
addition, their cloaking, using stealth technologies like PEGylation, allows them to 
circulate through blood for long periods of time without being cleared by the RES. 
When this cloaking technology is combined with the targeting ability, the therapeutic 
efficacy of the nanostructure is enhanced. Aiming at this enhancement, a great 
number of papers have presented the therapeutic effects of targeted SLNs and NLCs 
to the brain, but what it has to be noted here is that many of the results demonstrated 
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an accumulation of these brain-targeted nanoparticles to other body organs (e.g., liver, 
heart, lungs, etc.), that raises concerns whether their role is more beneficial than 
harmful. In our opinion, more specific targets, like overexpressed proteins or enzymes 
that lead to the activation or inactivation of pathways, have to be found, aiming at 
increasing the accumulation of these nanoparticles to the brain and at enhancing their 
therapeutic efficacy. Another point that has to be considered is the loading of these 
nanostructures. To date, most of the studies that have been published mostly 
demonstrate the encapsulation of drugs and no other therapeutics, like genes, 
enzymes, DNA/RNA, inorganic nanoparticles and others. In addition, these studies 
present the encapsulation of only one, or maybe two therapeutic substances. A 
potential reason for this is the inability of SLNs and NLCs for high loading of 
therapeutics in their lipid matrix, and these are among the main challenges that need 
to be resolved in order to increase their therapeutic efficacy in a targeted tissue. The 
loading of more than two different substances in the nanostructures or the 
combination of inorganic nanoparticles with other therapeutic molecules will 
transform the SLNs and the NLCs into multifunctional nanocarriers, rendering them 
able for a multi-approach treatment. Furthermore, the encapsulation of fluorescent 
dyes or fluorescent nanoparticles along with other therapeutic segments will transform 
these therapeutic nanostructures into theranostic nanostructures, that will be able to 
demonstrate in real time their therapeutic efficacy. 
Finally, it has to be noted that albeit SLNs and NLCs have greatly advanced during 
the last few years, to date none of these nanostructures have been able to successfully 
reach the clinical trials stage. Thus, advances in molecular biology that will offer 
novel targets, a better in-depth analysis on the causes of the CNS diseases, and a 
proper design for SLNs and NLCs taking into consideration the above-described 
limitations have to be carried out before being able to achieve the perfect lipid-based 
nano-delivery system. 
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